Non-coding RNAs (ncRNAs), once considered the 'dark matter' of the genome, have now emerged as pivotal regulators in cancer ...

HonorHealth Research Institute recently treated the first patient in a 50-site international clinical trial that will test a ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, presented data today from a study showing that its ...

A combination of pertuzimab and Enhertu can slow disease progression and improve survival in people with HER2-positive ...

Researchers from the University of Eastern Finland, Aalto University and the University of Oulu have developed a new ...

Some people with early stage cancers may be able to skip surgery after being treated with the immunotherapy drug dostarlimab, ...

A new study shows promising results for treating certain cancers with immunotherapy and completely avoiding surgery, ...

HonorHealth Research Institute's new downtown Phoenix laboratory has produced its first study, centered on a promising new ...

The pre-analytical workflow is one of the primary considerations in the successful use of liquid biopsies for cancer ...

Galleri blood test detects fifty cancers early via cfDNA analysis for adults 50+ with no symptoms, though not a standard ...

Fellow Health, a company focused on advancing male reproductive health through patient-centric testing solutions, today announced the presentation of four posters at the American Urological ...

The risk of developing blood cancer increases with age. The finding that a molecule from gut bacteria plays a part points to ...